General Information of Drug Combination (ID: DCV06I1)

Drug Combination Name
MK-1775 MK-4827
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs MK-1775   DM3WDZ5 MK-4827   DMLYGH4
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: HCT116
Zero Interaction Potency (ZIP) Score: 1.49
Bliss Independence Score: 2.36
Loewe Additivity Score: 2.95
LHighest Single Agent (HSA) Score: 2.69

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of MK-1775
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
MK-1775 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Wee1-like protein kinase (WEE1) TTJFOAL WEE1_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
MK-1775 Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Decreases Phosphorylation [5]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Response To Substance [5]
------------------------------------------------------------------------------------
Indication(s) of MK-4827
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 3 [4]
Breast cancer 2C60-2C65 Phase 2 [3]
Ewing sarcoma 2B52 Phase 1 [3]
MK-4827 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Poly [ADP-ribose] polymerase (PARP) TTEBCY8 NOUNIPROTAC Modulator [7]
------------------------------------------------------------------------------------
MK-4827 Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Metabolism [8]
Carboxylesterase 1 (CES1) DEB30C5 EST1_HUMAN Metabolism [9]
Beta-glucuronidase (GUSB) DEP54UE BGLR_HUMAN Metabolism [9]
------------------------------------------------------------------------------------
MK-4827 Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [10]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DCS4AFH OVCAR3 Investigative [1]
Adenocarcinoma DCZJ0WT A427 Investigative [1]
Adenocarcinoma DCUOZ58 NCIH2122 Investigative [1]
Adenocarcinoma DCUXGOA NCIH23 Investigative [1]
Adenocarcinoma DCIAJFG NCIH520 Investigative [1]
Adenocarcinoma DC1H17C COLO320DM Investigative [1]
Adenocarcinoma DCQH4L2 HT29 Investigative [1]
Adenocarcinoma DCXKP27 SW-620 Investigative [1]
Amelanotic melanoma DCB756T A2058 Investigative [1]
Germ cell tumour DC789LA PA1 Investigative [1]
Large cell lung carcinoma DCOT6P6 NCI-H460 Investigative [1]
Malignant melanoma DC1K916 A375 Investigative [1]
Malignant melanoma DCZ0GA3 RPMI7951 Investigative [1]
Malignant melanoma DCXL4GW SKMEL30 Investigative [1]
Non small cell carcinoma DCSSQGR SKMES1 Investigative [1]
Ovarian endometrioid adenocarcinoma DCEX7IO A2780 Investigative [1]
Ovarian serous cystadenocarcinoma DC8UK48 SK-OV-3 Investigative [1]
Prostate carcinoma DC94MO2 LNCAP Investigative [1]
Prostate carcinoma DCP6R64 VCAP Investigative [1]
Breast carcinoma DCMMN8B ZR751 Investigative [11]
Breast carcinoma DCPCLUJ KPL1 Investigative [11]
Breast carcinoma DCBUPX3 OCUBM Investigative [11]
Carcinoma DC0IWEK EFM192B Investigative [11]
Colon adenocarcinoma DC6J8HT LOVO Investigative [11]
Colon carcinoma DC39R1W RKO Investigative [11]
Invasive ductal carcinoma DCB4CSV T-47D Investigative [11]
Rectal adenocarcinoma DC03UAA SW837 Investigative [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 27 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7702).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT03602859) A Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST). U.S. National Institutes of Health.
5 Functional kinomics identifies candidate therapeutic targets in head and neck cancer. Clin Cancer Res. 2014 Aug 15;20(16):4274-88. doi: 10.1158/1078-0432.CCR-13-2858.
6 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
7 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
8 Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52(22):7170-85.
9 Summary of FDA-approved anticancer cytotoxic drugs at May 2019.
10 Autophagy up-regulated by MEK/ERK promotes the repair of DNA damage caused by aflatoxin B1. Toxicol Mech Methods. 2022 Feb;32(2):87-96. doi: 10.1080/15376516.2021.1968985. Epub 2021 Aug 26.
11 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.